The estimated Net Worth of Michael Rabinowitz is at least $828 Tisíc dollars as of 3 January 2023. Mr Rabinowitz owns over 13,325 units of Oramed Pharmaceuticals, Inc stock worth over $300,220 and over the last 2 years he sold ORMP stock worth over $167,229. In addition, he makes $360,180 as Chief Commercial Officer at Oramed Pharmaceuticals, Inc.
Mr has made over 1 trades of the Oramed Pharmaceuticals, Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 13,325 units of ORMP stock worth $167,229 on 3 January 2023.
The largest trade he's ever made was selling 13,325 units of Oramed Pharmaceuticals, Inc stock on 3 January 2023 worth over $167,229. On average, Mr trades about 6,663 units every 0 days since 2022. As of 3 January 2023 he still owns at least 126,143 units of Oramed Pharmaceuticals, Inc stock.
You can see the complete history of Mr Rabinowitz stock trades at the bottom of the page.
Michael Rabinowitz is the Chief Commercial Officer at Oramed Pharmaceuticals, Inc.
As the Chief Commercial Officer of Oramed Pharmaceuticals, Inc, the total compensation of Mr Rabinowitz at Oramed Pharmaceuticals, Inc is $360,180. There are 6 executives at Oramed Pharmaceuticals, Inc getting paid more, with Nadav Kidron having the highest compensation of $1,551,100.
Mr Rabinowitz is 56, he's been the Chief Commercial Officer of Oramed Pharmaceuticals, Inc since . There are 6 older and 8 younger executives at Oramed Pharmaceuticals, Inc. The oldest executive at Oramed Pharmaceuticals, Inc is Dr. Miriam Kidron Ph.D., 81, who is the Chief Scientific Officer & Director.
Over the last 17 years, insiders at Oramed Pharmaceuticals, Inc have traded over $7,377,390 worth of Oramed Pharmaceuticals, Inc stock and bought 881,642 units worth $3,583,418 . The most active insiders traders include Miriam Kidron, Leonard Sank a Nadav Kidron. On average, Oramed Pharmaceuticals, Inc executives and independent directors trade stock every 111 days with the average trade being worth of $97,149. The most recent stock trade was executed by Arie Mayer on 3 April 2023, trading 8,809 units of ORMP stock currently worth $19,556.
oramed pharmaceuticals (nasdaqcm:ormp) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 trials under the usfda, the company is seeking to revolutionize the treatment of diabetes. read more: http://www.oramed.com/investors/corporate-presentation watch: https://www.youtube.com/watch?v=5qchxtdv9eg
Oramed Pharmaceuticals, Inc executives and other stock owners filed with the SEC include: